In the steady-state, and despite targeting of tumor-associated fibroblast by the Pdgfrb-Cre.ert2 transgene (Figure 4B), both Tlr4fl/fl and Tlr4fl/flx Pdgfrb-Cre.ert2 mice exhibited identical tumor development with limited evidence of ongoing anti-tumor immunity (Figures 4C–4E). This evidence concerns the gene MAPK3 and neoplasm.